Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,068 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,062
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis123
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland198
- Alabama179
- Florida152
- Arizona150
- Massachusetts118
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,068 total
- NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06548152Recruiting
Quality of life for CLL patients on acalabrutinib
This study looks at quality of life in people with CLL who are taking acalabrutinib for the first time. It uses data already collected from a real-world database to see how patients feel and function.
Saint-AffriqueAges Any age - NCT06544798Enrolling by invitationPhase 2
Long-term follow-up of gene therapy for dry mouth
This study follows patients who previously received gene therapy for dry mouth caused by radiation. It aims to track long-term safety and any lasting benefits.
Gilbert, ArizonaAges 18 years+ - NCT06548607RecruitingEarly Phase 1
CAR-T therapy for autoimmune diseases
This early-phase trial tests a new CAR-T cell therapy that targets CD19 or both CD19 and BCMA to treat several autoimmune diseases like lupus, scleroderma, and vasculitis. It aims to calm the overactive immune system with a single infusion of your own engineered cells.
Bengbu, AnhuiAges 18–70 - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Duarte, CaliforniaAges 13–90 - NCT06534021RecruitingPhase 1
Study of IASO-782 for autoimmune blood disorders
This trial tests a new drug called IASO-782 for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) who haven't gotten better with standard treatments. The goal is to see if the drug can help control the immune system and improve blood counts.
Wuhan, HubeiAges 18–65 - NCT06534060RecruitingPhase 2
Testing MB-105 for CD5 positive T-cell lymphoma
This trial tests a new treatment called MB-105 for people with a type of T-cell lymphoma that has come back or not responded to other treatments. MB-105 is designed to target and attack cancer cells that have a specific marker called CD5 on their surface.
San Diego, CaliforniaAges 18 years+ - NCT06538064Recruiting
Study of HyQvia for Adults with CIDP in Routine Care
This study looks at how well HyQvia works for adults with CIDP in everyday medical practice. It includes people who are already using HyQvia or are switching to it.
Rancho Mirage, CaliforniaAges 18 years+ - NCT06546345Recruiting
Study of KeriFlex® implant for hand joint replacement
This trial tracks how well the KeriFlex® implant works over time in people who need a finger joint replacement due to arthritis or injury. It aims to see if the implant helps reduce pain and improve hand function.
BesançonAges 18 years+ - NCT06539182RecruitingPhase 2
DZD8586 for relapsed or refractory CLL/SLL
This trial tests a new oral drug called DZD8586 for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to previous treatment. The goal is to see if it can help control the disease.
Hefei, AnhuiAges 18 years+ - NCT06534918Recruiting
Nutrition and exercise coaching for cancer survivors
This study tests whether personalized nutrition and exercise coaching helps cancer survivors improve their health after treatment. If you have had breast, prostate, colorectal, or lymphoma cancer and finished your main treatment at least 6 months ago, you may qualify.
Miami, FloridaAges 18 years+ - NCT06533423Recruiting
Self-management help for new arthritis patients
This trial tests a self-management program for people recently diagnosed with certain types of arthritis. It aims to help you better manage your condition through education and support.
Glostrup MunicipalityAges 18–120 - NCT06538961Recruiting
Immune registry for BK virus in kidney transplant patients
This study is creating a registry to learn how the immune system responds to BK virus in people who have recently received a kidney transplant from a deceased donor. Researchers hope this information will help improve treatment for BK virus infections.
Richmond, VirginiaAges 18 years+ - NCT06549231RecruitingPhase 3
Rituximab and mycophenolate for scleroderma lung disease
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
ToursAges 18–100 - NCT06539312Recruiting
School program to help manage asthma
This trial tests a program that partners with schools to help children manage asthma better. It aims to improve asthma control and reduce hospital visits.
Buffalo, New YorkAges 4–13 - NCT06544954Recruiting
Grape study for heart and gut health in overweight women
This study tests whether eating California grapes can improve gut health and heart health in overweight or obese women who have been through menopause and may have type 2 diabetes or metabolic syndrome. You would need to eat grapes daily and provide blood and stool samples.
Davis, CaliforniaAges 45–70 - NCT06544018Recruiting
Sleep and body clock study for CAPS patients and family members
This study looks at how CAPS (a genetic condition that causes inflammation) affects sleep and daily body rhythms. It compares people with CAPS to healthy family members living in the same home, to understand differences without any treatment being tested.
BronAges 6 years+ - NCT06536452Recruiting
How blood cell production differs in CLL, MBL, and healthy people
This trial studies how the body makes blood cells in people with chronic lymphocytic leukemia (CLL), a related condition called monoclonal B-cell lymphocytosis (MBL), and in healthy volunteers matched by age. The goal is to understand differences that may help improve treatment or monitoring.
Rochester, MinnesotaAges 40 years+ - NCT06544785RecruitingPhase 2
Zanubrutinib plus obinutuzumab for untreated CLL or SLL
This trial tests a combination of two targeted drugs, zanubrutinib (a pill) and obinutuzumab (an infusion), for people with untreated CLL or SLL who need treatment. The goal is to see if this combination works well and is safe.
AlicanteAges 18 years+ - NCT06547372Recruiting
Dietary changes for eczema relief
This study tests whether a specific diet can help manage mild to moderate eczema. It involves eating whole foods provided by the researchers for a set period and tracking your skin health.
Singapore, SingaporeAges 21–65 - NCT06535412RecruitingPhase 1/Phase 2
Study of IMC-002 for active lupus
This study tests a new medicine, IMC-002, for people with active lupus that hasn't been controlled by standard treatments. It aims to see if the drug can reduce lupus activity and improve symptoms.
BeijingAges 18–65 - NCT06538181RecruitingPhase 1
Testing pacritinib for VEXAS syndrome
This trial tests a new drug called pacritinib for people with VEXAS syndrome, a rare autoinflammatory condition. The goal is to see if pacritinib can help control symptoms like rashes, joint pain, and low blood counts.
St Louis, MissouriAges 18 years+ - NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,068 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,217 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.